AIM ImmunoTech (NYSEAMERICAN:AIM) Raised to “Strong-Buy” at Zacks Research

AIM ImmunoTech (NYSEAMERICAN:AIM) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

AIM ImmunoTech Trading Down 3.7%

AIM ImmunoTech stock opened at $1.29 on Thursday. The stock has a 50 day moving average of $1.42 and a two-hundred day moving average of $3.28. AIM ImmunoTech has a twelve month low of $1.07 and a twelve month high of $36.00. The stock has a market capitalization of $3.68 million, a price-to-earnings ratio of -0.06 and a beta of 1.21.

AIM ImmunoTech (NYSEAMERICAN:AIM) last released its quarterly earnings results on Monday, November 17th. The company reported ($1.57) EPS for the quarter. The firm had revenue of $0.03 million during the quarter. Equities analysts predict that AIM ImmunoTech will post -0.3 earnings per share for the current year.

Institutional Trading of AIM ImmunoTech

An institutional investor recently bought a new position in AIM ImmunoTech stock. Sabby Management LLC acquired a new stake in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 28,855 shares of the company’s stock, valued at approximately $79,000. AIM ImmunoTech accounts for about 0.1% of Sabby Management LLC’s investment portfolio, making the stock its 22nd largest holding. Sabby Management LLC owned about 1.06% of AIM ImmunoTech as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 12.02% of the company’s stock.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.